PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC

被引:8
作者
Geum, Dong-Ho [1 ]
Hwang, Dae-Seok [1 ]
Lee, Chang-Hun [2 ]
Cho, Sung-Dae [3 ,4 ]
Jang, Min-A [5 ]
Ryu, Mi-Heon [6 ]
Kim, Uk-Kyu [1 ]
机构
[1] Pusan Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, 49 Busandaehak Ro, Yangsan 50612, South Korea
[2] Pusan Natl Univ, Sch Med, Dept Pathol, 49 Busandaehak Ro, Yangsan 50612, South Korea
[3] Seoul Natl Univ, Sch Dent, Dept Oral Pathol, Seoul 03080, South Korea
[4] Seoul Natl Univ, Dent Res Inst, Seoul 03080, South Korea
[5] Pusan Natl Univ, Dent & Life Sci Inst, 49 Busandaehak Ro, Yangsan 50612, South Korea
[6] Pusan Natl Univ, Dept Oral Pathol, Dent & Life Sci Inst, Sch Dent, 49 Busandaehak Ro, Yangsan 50612, South Korea
来源
LIFE-BASEL | 2022年 / 12卷 / 02期
基金
新加坡国家研究基金会;
关键词
programmed cell death ligand 1; oral squamous cell carcinoma; prognosis; immunotherapy; TUMOR PROGRESSION; CANCER CELLS; APOPTOSIS; IMMUNOTHERAPY; LIGANDS;
D O I
10.3390/life12020238
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule that inhibits immune responses. The physiological and prognostic role of the PD-L1 signaling pathway in the oral maxillofacial region is unclear. This study aimed to investigate the role of PD-L1 in the progression of oral squamous cell carcinoma (OSCC). Furthermore, clinicopathological factors related to PD-L1 expression were examined in patients with OSCC through immunohistochemistry (IHC) of tissue sections and through an in vitro study in OSCC cells. The medical records, radiographic findings, and mortality referrals of 81 patients obtained from the National Statistical Office were reviewed. IHC was performed on tissue specimens of these patients to determine the expression levels of PD-L1, which showed significant statistical differences based on age, tumor size, TNM stage, cervical lymph node metastasis, and locoregional recurrence. Patients with a high PD-L1 expression had significantly poorer survival rates. Multivariate analysis using the Cox proportional model confirmed the high relative risk ratio for high PD-L1 expression, TNM stage, and neck node metastasis, all of which were significantly associated with a poor prognosis in patients with OSCC. The in vitro study showed that SAS and YD38 cells transfected with PD-L1 siRNA had significantly increased apoptosis, reduced proliferative capacity, and tumorigenicity.
引用
收藏
页数:19
相关论文
共 30 条
[1]   AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells [J].
Abdelhamed, Sherif ;
Ogura, Keisuke ;
Yokoyama, Satoru ;
Saiki, Ikuo ;
Hayakawa, Yoshihiro .
JOURNAL OF CANCER, 2016, 7 (12) :1579-1586
[2]   PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer [J].
Bian, Chunan ;
Liu, Zonghang ;
Li, Dakou ;
Zhen, Lifeng .
ONCOLOGY LETTERS, 2018, 15 (06) :9655-9662
[3]   Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion [J].
Blank, Christian ;
Mackensen, Andreas .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :739-745
[4]   Cytoplasmic HuR expression: Correlation with cellular inhibitors of apoptosis protein-2 expression and clinicopathologic factors in oral squamous cell carcinoma cells [J].
Cha, Jeong-Dan ;
Kim, Hee-Kyeong ;
Cha, In-Ho .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (08) :1168-1175
[5]   Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma [J].
Cho, Young-Ah ;
Yoon, Hye-Jung ;
Lee, Jae-Il ;
Hong, Sam-Pyo ;
Hong, Seong-Doo .
ORAL ONCOLOGY, 2011, 47 (12) :1148-1153
[6]   Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway [J].
Choi, Byul Bo Ra ;
Choi, Jeong-Hae ;
Kim, Uk Kyu ;
Hwang, Dae Seok ;
Kim, Gyoo Cheon .
ARCHIVES OF ORAL BIOLOGY, 2021, 125
[7]   Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort [J].
Chow, Laura Q. M. ;
Haddad, Robert ;
Gupta, Shilpa ;
Mahipal, Amit ;
Mehra, Ranee ;
Tahara, Makoto ;
Berger, Raanan ;
Eder, Joseph Paul ;
Burtness, Barbara ;
Lee, Se-Hoon ;
Keam, Bhumsuk ;
Kang, Hyunseok ;
Muro, Kei ;
Weiss, Jared ;
Geva, Ravit ;
Lin, Chia-Chi ;
Chung, Hyun Cheol ;
Meister, Amy ;
Dolled-Filhart, Marisa ;
Pathiraja, Kumudu ;
Cheng, Jonathan D. ;
Seiwert, Tanguy Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3838-+
[8]   Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Aisner, Dara L. ;
Akerley, Wallace ;
Bauman, Jessica ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
DeCamp, Malcolm M. ;
Dilling, Thomas J. ;
Dobelbower, Michael ;
Doebele, Robert C. ;
Govindan, Ramaswamy ;
Gubens, Matthew A. ;
Hennon, Mark ;
Horn, Leora ;
Komaki, Ritsuko ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Leal, Ticiana A. ;
Leisch, Leah J. ;
Lilenbaum, Rogerio ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Martins, Renato ;
Otterson, Gregory A. ;
Reckamp, Karen ;
Riely, Gregory J. ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Stevenson, James ;
Swanson, Scott J. ;
Tauer, Kurt ;
Yang, Stephen C. ;
Gregory, Kristina ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (04) :504-535
[9]   Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use [J].
Ferris, Robert L. ;
Licitra, Lisa ;
Fayette, Jerome ;
Even, Caroline ;
Blumenschein, George, Jr. ;
Harrington, Kevin J. ;
Guigay, Joel ;
Vokes, Everett E. ;
Saba, Nabil F. ;
Haddad, Robert ;
Ramkumar, Shanmugasundaram ;
Russell, Jeffery ;
Brossart, Peter ;
Tahara, Makoto ;
Colevas, A. Dimitrios ;
Concha-Benavente, Fernando ;
Lynch, Mark ;
Li, Li ;
Gillison, Maura L. .
CLINICAL CANCER RESEARCH, 2019, 25 (17) :5221-5230
[10]   Immunology and Immunotherapy of Head and Neck Cancer [J].
Ferris, Robert L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) :3293-+